Skip to content
20-F

Annual Report (Foreign)

ASLAN Pharmaceuticals Limited

0000950170-24-043860

← back to feed
Filed
Apr 12, 2024 12:00 AM ET
Period of report
—

On SEC.gov

Filing index ↗

Financials in this filing

Metric Period Value
Dividends Paid FY 2023 · Dec 31, 2023 $0
Dividends Paid FY 2023 · Dec 31, 2022 $0
Dividends Paid FY 2023 · Dec 31, 2021 $0
Operating Cash Flow FY 2023 · Dec 31, 2023 −$46.64M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$38.41M
Operating Cash Flow FY 2023 · Dec 31, 2021 −$34M
Cash And Equivalents FY 2023 · Dec 31, 2023 $21.25M
Cash And Equivalents FY 2023 · Dec 31, 2022 $56.9M
Cash And Equivalents FY 2023 · Dec 31, 2021 $90.17M
Cash And Equivalents FY 2023 · Dec 31, 2020 $14.32M
Stockholders Equity FY 2023 · Dec 31, 2023 −$13.29M
Stockholders Equity FY 2023 · Dec 31, 2022 $8.37M
Stockholders Equity FY 2023 · Dec 31, 2021 $57.3M
Stockholders Equity FY 2023 · Dec 31, 2020 −$10.15M
Current Liabilities FY 2023 · Dec 31, 2023 $13.11M
Current Liabilities FY 2023 · Dec 31, 2022 $23.16M
Total Liabilities FY 2023 · Dec 31, 2023 $37.91M
Total Liabilities FY 2023 · Dec 31, 2022 $52.82M
Current Assets FY 2023 · Dec 31, 2023 $24.13M
Current Assets FY 2023 · Dec 31, 2022 $60.88M
Total Assets FY 2023 · Dec 31, 2023 $24.63M
Total Assets FY 2023 · Dec 31, 2022 $61.19M
Eps Diluted FY 2023 · Dec 31, 2023 −$0.11
Eps Diluted FY 2023 · Dec 31, 2022 −$0.15
Eps Diluted FY 2023 · Dec 31, 2021 −$0.10
Eps Basic FY 2023 · Dec 31, 2023 −$0.11
Eps Basic FY 2023 · Dec 31, 2022 −$0.15
Eps Basic FY 2023 · Dec 31, 2021 −$0.10
Rd Expense FY 2023 · Dec 31, 2023 $42.5M
Rd Expense FY 2023 · Dec 31, 2022 $38M
Rd Expense FY 2023 · Dec 31, 2021 $22.02M
Net Income FY 2023 · Dec 31, 2023 −$44.22M
Net Income FY 2023 · Dec 31, 2022 −$51.38M
Net Income FY 2023 · Dec 31, 2021 −$31.59M
Operating Income FY 2023 · Dec 31, 2023 −$43.74M
Operating Income FY 2023 · Dec 31, 2022 −$47.88M
Operating Income FY 2023 · Dec 31, 2021 −$33.85M
Gross Profit FY 2023 · Dec 31, 2023 $12M